Collins Stewart

Collins Stewart has lowered the price target on Google (NASDAQ: GOOG) from $795 to $750 and maintains its Buy rating.

Collins Stewart has initiated coverage on Ardea Biosciences (NASDAQ: RDEA) with a Buy rating and $30 price target.

Collins Stewart has initiated coverage on Digital Realty Trust (NYSE: DLR) with a Neutral rating and $65 price target.

Collins Stewart reiterates its Buy rating and $210 target price on IBM (NYSE: IBM) as the company is expected to delivers 4Q results in line with forecasts. Collins Stewart says, "Our checks suggest IBM's 4Q closed out in-line with our prior expectations. Our concern heading into last quarter was...

Collins Stewart has lowered the price target on Williams-Sonoma (NYSE: WSM) from $55 to $53 and maintains its Buy rating.

Collins Stewart released a report concerning Auxilium Pharmaceuticals' (NASDAQ: AUXL) CEO putting focus on execution in only his fourth week on the job. “[Adrian] Adams is focused on the following: 1) the commercial execution of Testim and Xiaflex; 2) advancing new indications for Xiaflex,...

According to a research report released by Collins Stewart, SYNNEX (NYSE: SNX) enjoyed a nice quarter with revenue of $2.84B up 15% y/y. Collins Stewart states, “On January 5th we commented that the distribution names including SYNNEX would see a benefit from the HDD shortage situation as prices...

Collins Stewart has lowered the price target on Tiffany & Co. (NYSE: TIF) from $72 to $66 and maintains its Neutral rating.

Collins Stewart has upgraded MEMC Electronic Materials (NYSE: WFR) from Neutral to Buy and maintains its $5.50 price target.

A report from Collins Stewart initiates coverage on Anthera Pharmaceuticals (NASDAQ: ANTH) with a Buy rating and a $13 price target. The report states, “ANTH has two value-driving assets in varespladib (P3) for acute coronary syndrome (ACS) and blisibimod (bmod; P2b) for lupus, with data from both...

A report from Collins Stewart reiterates its Neutral rating and $3 price target on Sprint Nextel (NYSE: S). The report states, “With the December 1st deadline, Sprint yesterday again continued to reverse course following the October 7th analyst day by announcing that it would provide funding to...

Collins Stewart has initiated coverage on Anthera Pharmaceuticals (NASDAQ: ANTH) with a Buy rating and $13 price target.

A report from Collins Stewart initiates coverage on Sagent Pharmaceuticals (NASDAQ: SGNT) with a Buy rating and $25 price target. The report states, “We estimate the launch of critical shortage drugs could potentially add $225MM+ in sales and contribute $1.80+ in EPS annually for SGNT… SGNT's CEO...

Collins Stewart has published a research report on Perrigo (NASDAQ: PRGO) after the company announced that it has received FDA approval on a store-brand for Mucinex. In the report, Collins Stewart writes, "We are reiterating our Buy rating and $117 price target for PRGO shares post the company's...

A report from Collins Stewart reiterates its Neutral rating and $2 price target and JA Solar (NASDAQ: JASO). The report states, “JASO's core solar cell business is expected to remain under severe pressure in the quarters ahead, as demand for cells has weakened and competition brought on by over-...